P
Pulmatrix
Pulmatrix develops inhaled therapies for the treatment, prevention and transmission of infectious and progressive respiratory diseases
About Pulmatrix
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative inhaled therapies for serious pulmonary and non-pulmonary diseases. Utilizing its patented iSPERSE technology, Pulmatrix aims to enhance patient care by delivering therapeutics directly to the lungs. The company operates in the healthcare sector, primarily targeting patients with severe respiratory conditions. Pulmatrix's business model involves the research, development, and commercialization of its proprietary drug formulations. Revenue is generated through partnerships, licensing agreements, and eventual product sales. The company collaborates with partners like Sensory Cloud to market and distribute products such as FEND, an over-the-counter nasal hygiene product designed to suppress exhaled airborne particles. Pulmatrix's pipeline includes various therapeutic candidates aimed at addressing unmet medical needs in respiratory health.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2014
Open roles
Pulmatrix in the Lexington ecosystem
The Pulmatrix office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Polaris Partners
5AM Ventures
Novartis Venture Fund
ARCH Venture Partners
Series B and later1 investor entered at this stage
Altitude Life Science Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
See Pulmatrix on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Pulmatrix nears year-end merger with Eos as cash falls to $1.4M
